The Oncologist：Palbociclib联合内分泌治疗HR+/HER2-转移性乳腺癌的安全性分析：来自PALOMA系列5年随访综合分析更新

2021-05-15 yd2015 MedSci原创

yd2015

通过5年的长期综合分析，证实Palbociclib联合内分泌治疗HR+/HER2-转移性乳腺癌是一种安全的治疗方式。

Palbociclib是一种细胞周期蛋白依赖性激酶(CDK)4/6抑制剂，与内分泌(ET)联合治疗批准用于治疗激素受体阳性(HR)/人表皮生长因子受体2阴性（HER2−）晚期乳腺癌(ABC)患者。在PALOMA系列（PALOMA-1，PALOMA-2和PALOMA-3）临床研究中，Palbociclib联合来曲唑或氟维司群较单药来曲唑或氟维司群改善HR+/HER2-转移性乳腺癌患者的无进展生存期（PFS）。虽然中生存期（OS）没有获得统计学差异，但是数值上Palbociclib联合来曲唑或氟维司群获得较长的OS。除了关注患者获得生存外，还有关注治疗相关不良事件以及生活质量。因为在真实世界中，CDK4/6 抑制剂可增加间质性肺炎和静脉血栓形成，而后者可导致更差的PFS和 OS。近期，The Oncologist杂志发表了Palbociclib治疗安全性的数据更新（基于PALOMA系列研究）。

文章更新了PALOMA系列研究中综合分析Palbociclib联合治疗5年随访安全性。数据截止时间：PALOMA-1：2017年12月21日；PALOMA-2：2017年5月31日；PALOMA-3：2018年4月13日。研究数据表明，Palbociclib联合内分泌每年治疗人次为1,421.6（n=872），而内分泌单药为528.4 (n = 471)。Palbociclib联合内分泌组中，36%患者治疗超过24个月，22.4%患者超过36个月，1.7%患者治疗超过48个月，0.7%患者治疗超过60个月，大部分患者是来自PALOMA-2试验。内分泌单药组中，20.2%患者治疗超过24个月，10.2%患者超过36个月，0.8%患者治疗超过48个月，0.4%患者治疗超过60个月。联合组中中位治疗持续时间为14.8个月 (范围： 0–84.4) ，而内分泌单药组为2.9个月 (范围： 0–74.7) 。

治疗持续时间对比

Palbociclib联合内分泌组发生任何级别粒细胞减少和感染分别为82.1% 和59.2%, 而内分泌单药组分别为5.1% 和 39.5%。3/4级感染的危险比为1.6（p=0.0995），3/4级病毒性感染危险比为1.8 (p = .4358) ，感染的危险比为1.4 (p = .0001) ，中性粒细胞减少危险比为30.8 (p < .0001)。Palbociclib联合内分泌组发生发热性粒细胞减少比例为1.4%。两组任何级别的血液性不良事件在治疗的第一年达到顶峰，在随后的5年治疗中较平稳。Palbociclib联合内分泌组发生间质性肺炎有13例患者，而内分泌单药治疗中有3例患者。

内分泌治疗不良事件

联合或单药治疗相关不良事件

综上，通过5年的长期综合分析，证实Palbociclib联合内分泌治疗HR+/HER2-转移性乳腺癌是一种安全的治疗方式。

原始出处：

Richard S Finn , Hope S Rugo , Karen A Gelmon，et al. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. Oncologist. 2021 May;26(5):e749-e755.doi: 10.1002/onco.13684.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (10)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2022-03-08 minlingfeng

#Oncol#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2021-05-16 luwei00

#HER2-#

29 0
[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2021-10-14 一叶知秋

#分泌#

32 0
[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2021-12-15 tm10051981

#5年随访#

58 0
[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2021-06-09 西红柿子首富

学习学习一下

70 0
[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2021-05-17 ysjykql

#palbociclib#

34 0
[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2021-05-17 1249842em09(暂无昵称)

#转移性#

23 0
[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2021-05-17 july_977

#GIST#

24 0
[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2021-05-17 tjlyp

激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受

56 0
[GetPortalCommentsPageByObjectIdResponse(id=1866090, encodeId=cd8818660909d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 08 04:59:00 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982539, encodeId=4d4d1982539ba, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Sun May 16 09:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682669, encodeId=7e891682669a5, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 14 12:59:00 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914424, encodeId=4ab11914424c1, content=<a href='/topic/show?id=ecd31481c3' target=_blank style='color:#2F92EE;'>#5年随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1481, encryptionId=ecd31481c3, topicName=5年随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Wed Dec 15 19:59:00 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972282, encodeId=46be9e2282d0, content=学习学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210727/d027545c5fe24e5abcd4a88d24ae6cb7/24ea01514ea54b3e9cbbcbe6c40524c7.jpg, createdBy=c3ad5476755, createdName=西红柿子首富, createdTime=Wed Jun 09 21:23:56 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372326, encodeId=96a013e2326d8, content=<a href='/topic/show?id=48cd1369065' target=_blank style='color:#2F92EE;'>#palbociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13690, encryptionId=48cd1369065, topicName=palbociclib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386763, encodeId=79ee1386e634c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455172, encodeId=239814551e20f, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Mon May 17 13:59:00 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966190, encodeId=16c796619047, content=激素阳性的乳腺癌，采用CDK4/6联合内分泌治疗值得期待，希望价格患者可以承受, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210425/188bc6472a1742d09222864964fb4cca/508399781e704ed38acfdf86b724aef5.jpg, createdBy=d0e75483900, createdName=tjlyp, createdTime=Mon May 17 09:03:02 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038294, encodeId=627b103829431, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 16 01:59:00 CST 2021, time=2021-05-16, status=1, ipAttribution=)]
2021-05-16 anti-cancer

谢谢梅斯分享这么多精彩信息

44 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

The Oncologist：Palbociclib联合内分泌治疗HR+/HER2-转移性乳腺癌的安全性分析：来自PALOMA系列5年随访综合分析更新

相关资讯

拓展阅读

科室

工具

服务